drugset / Trial / NCT01329289
SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if adding SOM230 LAR to bortezomib and dexamethasone is better than bortezomib and dexamethasone alone and if it should be investigated further.
Timeline
- Start
- 2011-12
- Primary completion
- 2012-02
- Completion
- 2012-02
Outcome
Outcome not reported
Stopped: “Clinical trial being transferred to Columbia University with the Investigator.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pasireotide | Other / unclassified | 60 mg | Intramuscular |
| Background | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Background | Dexamethasone | Small molecule | 20 mg | Oral |